3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction

Primary human hepatocytes (PHHs) have been the gold standard in vitro model for the human liver and are crucial to predict hepatic drug-drug interactions. The aim of this work was to assess the utility of 3D spheroid PHHs to study induction of important cytochrome P450 (CYP) enzymes and drug transporters. 3D spheroid PHHs from three different donors were treated for four days with rifampicin, dicloxacillin, flucloxacillin, phenobarbital, carbamazepine, efavirenz, omeprazole or β-naphthoflavone. Induction of CYPs 1A1, 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, P-gp/ABCB1, MRP2/ABCC2, ABCG2, OCT1/SLC22A1, SLC22A7, SLCO1B1 and SLCO1B3 were evaluated at mRNA and protein levels. Enzyme activity of CYP3A4, CYP2B6, CYP2C19 and CYP2D6 were also assessed. Induction of CYP3A4 protein and mRNA correlated well for all donors and compounds and had a maximal induction of 5-to 6-fold for rifampicin, which closely correlates to induction observed in clinical studies. Similar estimates were found for dicloxacillin and flucloxacillin, which also correlates to findings from clinical studies. Rifampicin induced the mRNA of CYP2B6 and CYP2C8 by 9- and 12-fold, while the protein levels of these CYPs reached 2- and 3-fold induction, respectively. Rifampicin induced CYP2C9 protein by 1.4-fold, while the induction of CYP2C9 mRNA was over 2-fold in all donors. Rifampicin induced ABCB1, ABCC2 and ABCG2 by 2-fold. In conclusion, 3D spheroid PHHs is a valid model to investigate mRNA and protein induction of hepatic drug metabolizing enzymes and transporters, and this model provides a solid basis to study induction of CYPs and transporters, which translates to clinical relevance.

[1]  A. Bittner,et al.  Characterization of JNJ-2482272 [4-(4-Methyl-2-(4-(Trifluoromethyl)Phenyl)Thiazole-5-yl) Pyrimidine-2-Amine] As a Strong Aryl Hydrocarbon Receptor Activator in Rat and Human , 2022, Drug Metabolism and Disposition.

[2]  L. Alifrangis,et al.  In Vitro CYP450 Enzyme Downregulation by GLP-1/Glucagon Coagonist Does Not Translate to Observed Drug-Drug Interactions in the Clinic , 2022, Drug Metabolism and Disposition.

[3]  V. Lauschke,et al.  Multi-Well Array Culture of Primary Human Hepatocyte Spheroids for Clearance Extrapolation of Slowly Metabolized Compounds , 2022, The AAPS Journal.

[4]  Johan U. Lind,et al.  Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives , 2022, Pharmacological Reviews.

[5]  P. Artursson,et al.  Conditions for maintenance of hepatocyte differentiation and function in 3D cultures , 2021, iScience.

[6]  M. Ingelman-Sundberg,et al.  Primary Human Hepatocyte Spheroids as an In Vitro Tool for Investigating Drug Compounds with Low Hepatic Clearance , 2021, Drug Metabolism and Disposition.

[7]  A. D. Rodrigues,et al.  Exploring the Use of Serum‐Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Hepatic Cytochromes P450 and Organic Anion Transporting Polypeptides , 2021, Clinical pharmacology and therapeutics.

[8]  H. Yoo,et al.  Chemical‐based primary human hepatocyte monolayer culture for the study of drug metabolism and hepatotoxicity: Comparison with the spheroid model , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  Y. Lai,et al.  Transporter Gene Regulation in Sandwich Cultured Human Hepatocytes Through the Activation of Constitutive Androstane Receptor (CAR) or Aryl Hydrocarbon Receptor (AhR) , 2021, Frontiers in Pharmacology.

[10]  J. Hakkola,et al.  Inhibition and induction of CYP enzymes in humans: an update , 2020, Archives of Toxicology.

[11]  T. Andersson,et al.  Primary human hepatocytes spheroid model as a 3D in vitro platform for metabolism studies. , 2020, Journal of pharmaceutical sciences.

[12]  J. Gan,et al.  Hepatocyte spheroids as a viable in vitro model for recapitulation of complex in vivo metabolism pathways of loratadine in humans , 2020, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  Y. Sugiyama,et al.  Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications , 2020, Clinical pharmacology and therapeutics.

[14]  D. Stresser,et al.  Enrichment-free High-throughput Liquid Chromatography–Multiple-Reaction Monitoring Quantification of Cytochrome P450 Proteins in Plated Human Hepatocytes Direct from 96-Well Plates Enables Routine Protein Induction Measurements , 2020, Drug Metabolism and Disposition.

[15]  Sabine U. Vorrink,et al.  Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three‐Dimensional Spheroid Cultures of Primary Human Hepatocytes , 2020, Clinical pharmacology and therapeutics.

[16]  A. D. Rodrigues,et al.  Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions? , 2019, Drug Metabolism and Disposition.

[17]  R. Subramanian,et al.  Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo , 2019, Drug Metabolism and Disposition.

[18]  D. Tweedie,et al.  Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates , 2019, Drug Metabolism and Disposition.

[19]  M. Ingelman-Sundberg,et al.  Three-Dimensional Spheroid Primary Human Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells. , 2018, Tissue engineering. Part C, Methods.

[20]  S. Krähenbühl,et al.  Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug , 2018, Front. Pharmacol..

[21]  D. Tweedie,et al.  Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance , 2018, Drug Metabolism and Disposition.

[22]  Anastacia M. Garcia,et al.  Optimization of phenol-chloroform RNA extraction , 2018, MethodsX.

[23]  T. Hosaka,et al.  Characterization of CYP2C Induction in Cryopreserved Human Hepatocytes and Its Application in the Prediction of the Clinical Consequences of the Induction. , 2018, Journal of pharmaceutical sciences.

[24]  P. Artursson,et al.  Direct Quantification of Cytochromes P450 and Drug Transporters—A Rapid, Targeted Mass Spectrometry-Based Immunoassay Panel for Tissues and Cell Culture Lysates , 2018, Drug Metabolism and Disposition.

[25]  Sabine U. Vorrink,et al.  Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  A. Pottegård,et al.  Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro , 2018, British journal of clinical pharmacology.

[27]  Frank Jacobs,et al.  Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  F. Weiß,et al.  Concept: The Use of Targeted Immunoaffinity Proteomics for Routine Assessment of In Vitro Enzyme Induction. , 2017, Journal of pharmaceutical sciences.

[29]  D. Tweedie,et al.  Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control , 2017, Drug Metabolism and Disposition.

[30]  Olof Beck,et al.  Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  Benjamin Berger,et al.  Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail , 2016, Front. Pharmacol..

[32]  Souren Mkrtchian,et al.  Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation , 2016, Hepatology.

[33]  Hongbing Wang,et al.  Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry Perspective , 2016, Drug Metabolism and Disposition.

[34]  M. Ingelman-Sundberg,et al.  Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease , 2016, Scientific Reports.

[35]  Niresh Hariparsad,et al.  Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes , 2016, Drug Metabolism and Disposition.

[36]  S. Krähenbühl,et al.  Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study , 2015, Clinical Pharmacokinetics.

[37]  Z. Dvořák,et al.  Omeprazole and Lansoprazole Enantiomers Induce CYP3A4 in Human Hepatocytes and Cell Lines via Glucocorticoid Receptor and Pregnane X Receptor Axis , 2014, PloS one.

[38]  M. Shimizu,et al.  Evaluation of 23 Lots of Commercially Available Cryopreserved Hepatocytes for Induction Assays of Human Cytochromes P450 , 2014, Drug Metabolism and Disposition.

[39]  Adam S. Hayward,et al.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.

[40]  Dave T. Gerrard,et al.  Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation , 2013, Hepatology.

[41]  T. Skaar,et al.  Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent , 2013, The Pharmacogenomics Journal.

[42]  Y. Daali,et al.  Oral Flurbiprofen Metabolic Ratio Assessment Using a Single‐Point Dried Blood Spot , 2012, Clinical pharmacology and therapeutics.

[43]  J. Brockmöller,et al.  Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers , 2009, Clinical pharmacology and therapeutics.

[44]  E. Kharasch,et al.  Single‐point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam , 2005, Clinical pharmacology and therapeutics.

[45]  W. Ambrosius,et al.  The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity , 2003, Clinical pharmacology and therapeutics.

[46]  M. Gibaldi,et al.  The mechanism of the warfarin‐rifampin drug interaction in humans , 1987, Clinical pharmacology and therapeutics.

[47]  J. Sahi,et al.  Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes , 2009, Journal of biochemical and molecular toxicology.

[48]  K. Johnson.  An Update. , 1984, Journal of food protection.